What sector does Vertex Pharmaceuticals belong to?

Vertex Pharmaceuticals operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of VRTX?

As of the latest available quote, VRTX traded at $515.44. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of VRTX?

Vertex Pharmaceuticals has a price-to-earnings (P/E) ratio of about 30.04. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of VRTX?

The market capitalisation of Vertex Pharmaceuticals is approximately $133.01B.

Is Vertex Pharmaceuticals profitable?

For its latest reported financial year, Vertex Pharmaceuticals recorded a net profit margin of about 32.94%.

Does VRTX pay a dividend?

Vertex Pharmaceuticals does not currently show a dividend yield in our data.

What is the return on equity (ROE) of VRTX?

Vertex Pharmaceuticals has a return on equity (ROE) of about 19.52%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of VRTX?

Over the past 52 weeks, VRTX has traded between a low of $374.17 and a high of $560.25.

Vertex Pharmaceuticals

VRTX US Health Care Biotechnology

S&P 500 Nasdaq 100

$515.44

+0.17%

Delayed · cached 15 min

Fair value analysis

VRTX

Vertex Pharmaceuticals

$515.44

Close used for this calculation

$277.98Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

60/100

Profitability25/25

Returns9/25

Balance Sheet18/25

Efficiency8/25

Growth12/25

Good

Quality radar

Consensus fair value

$277.98

Above FV

▼ -46.1% against the close used

Model range $165.33 – $459.60

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$165.33Fair value$277.98Bull$459.60

FairClose

52-week traded range

52W low $376.6252W high $557.96

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Vertex Pharmaceuticals closed at $515.44, 85.4% above the consensus fair value of $277.98 drawn from 8 valuation models.

Financial DNA score 60/100 — Good. P/E of 33.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$245.67

-52.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$165.33

-67.9%

√(22.5 × EPS × BVPS)

EPS=15.32, BVPS=79.3 · outside Graham range (P/E 33.6, P/B 6.5) — asset-light, treat as a rough floor

P/E Fair Value

$306.40

-40.6%

EPS × 20x (sector P/E)

EPS=15.32, Sector P/E=20x

Peter Lynch (PEG)

$459.60

-10.8%

EPS × Growth% (PEG = 1 is fair)

EPS=15.32, g=30%

EV/EBITDA

$305.75

-40.7%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=4.38B

Book Value (P/B)

$268.03

-48.0%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=79.3, ROE=19.5%, g=6%, r=10%

Reverse DCF

$515.44

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 14.2% | Historical: 40%

Margin of Safety

$179.35

-65.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=239.13, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer